Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;43(4):1056-1062.
doi: 10.1002/hed.26563. Epub 2021 Feb 19.

Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy

Kaveh Zakeri  1 , Huili Wang  1 , Jung Julie Kang  1 , Anna Lee  1 , Paul Romesser  1 , Nader Mohamed  1 , Daphna Gelblum  1 , Eric Sherman  2 , Lara Dunn  2 , Jay Boyle  3 , Richard Wong  3 , Linda Chen  1 , Yao Yu  1 , C Jillian Tsai  1 , Sean M McBride  1 , Nadeem Riaz  1 , Nancy Lee  1
Affiliations

Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy

Kaveh Zakeri et al. Head Neck. 2021 Apr.

Abstract

Background: Proton beam radiation therapy (PBRT) has dosimetric advantages compared to photon radiation therapy for the treatment of major salivary gland tumors (MSGTs).

Methods: Patients with non-metastatic MSGTs treated at a single proton therapy center from October 2013 to October 2018 were retrospectively reviewed.

Results: Sixty-eight patients with MSGTs were included and the most common site and histology were the parotid gland (75.0%) and adenoid cystic carcinoma (22.1%), respectively. The 3-year rates of locoregional control, progression-free survival, and overall survival were 95.1% (95% CI: 89.9%-100.0%), 80.7% (70.2%-92.7%), and 96.1% (95% CI: 90.9%-100.0%), respectively.

Conclusion: In a large cohort of MSGTs treated with PBRT, the rates of locoregional control were high in short-term follow-up and treatment was well tolerated.

Keywords: cancer; proton therapy; radiation; salivary gland; survival.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Incidence of locoregional failure.
Figure 2.
Figure 2.
Kaplan-Meier plots of progression-free survival (a) and overall survival (b).
See this image and copyright information in PMC

References

    1. Adelstein DA, Koyfman SA, El-Naggar AK, Hanna EY. Biology and management of salivary gland cancers. Semin Radiat Oncol. 2012; 22:245–253. - PubMed
    1. North CA, Lee DJ, Piantadosi S, et al. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1990;18:1319–1326. - PubMed
    1. Garden AS, el-Naggar AK, Morrison WH, et al. Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 1997;79–85. - PubMed
    1. Ali S, Palmer FL, Katabi N, et al. Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope. 2017. Oct;127(10):2265–2269. - PMC - PubMed
    1. Terhaard CHJ, Lubsen H, Van Der Tweel, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch Head and Neck Oncology Cooperative Group. Head Neck 2004;26:681–693. - PubMed